Affiliation:
1. South Ural State Medical University
Abstract
Aim. To study the prognostic significance of atherosclerosis of one and several vascular systems in patients with high and very high cardiovascular risk (CVR).Material and methods. The study included 171 patients with high (26,9%) and very high (73,1%) CVR. All patients underwent duplex ultrasound of the carotid and lower limb arteries. The composite endpoint (CE) was cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and coronary revascularization.Results. The follow-up period lasted 31,1 (17,8; 47,9) months. CE events occurred in 29 (16,9%) patients: cardiovascular death — 3 (1,75%) patients; nonfatal myocardial infarction — 7 (4,09%) patients; nonfatal stroke — 6 (3,51%) patients; coronary revascularization — 13 (7,60%) patients. Cumulative survival of patients with high and very high CVR with atherosclerotic plaques in the same vascular system did not significantly differ from that in patients with intact peripheral arteries (p=0,977). The event-free survival of patients with combined lesions of the carotid and lower limb arteries was significantly lower in comparison with patients with one vascular system involvement (p=0,011). The combined lesion of the carotid and lower limb arteries was associated with an increase in the relative risk (RR) of adverse cardiovascular events (RR, 3,15 (95% CI, 1,02-9,74; p=0,046), adjusted for sex, age, and peripheral arterial disease symptoms.Conclusion. In patients with high and very high CVR, atherosclerotic lesion of two vascular systems of peripheral arteries is associated with an increase in the RR of adverse cardiovascular events, adjusted for sex, age, and peripheral arterial disease symptoms. The presence of atherosclerotic plaques in one vascular bed was not associated with an increase in the risk of CE events.
Subject
Cardiology and Cardiovascular Medicine
Reference25 articles.
1. Lazzeroni D, Coruzzi P. Risk stratification in secondary cardiovascular prevention. Minerva Cardioangiol. 2018;66(4):471-6. doi:10.23736/S0026-4725.18.04648-0.
2. Boitsov SA, Pogosova NV, Bubnova MG, et al. Cardiovascular prevention 2017 National guidelines. Russ J Cardiol. 2018;23(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122.
3. Annemans L, Packard CJ, Briggs A, Ray KK. ‘Highest risk-hig-hest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. Eur Heart J. 2018;39(27):2546-50. doi:10.1093/eurheartj/ehx710.
4. Kontsevaya AV, Mukaneeva DK, Myrzamatova AO, et al. Economic damage of risk factors associated with morbidity and mortality from major chronic non-communicable diseases in Russia in 2016. Cardiovascular Therapy and Prevention. 2020;19(1):48-55. (In Russ.) doi:10.15829/1728-8800-2020-1-2396.
5. Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations. VII revision. Atherosclerosis and dyslipidemia. 2020;1(38):7-40. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献